MARKET

IMGN

IMGN

ImmunoGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.46
-0.49
-5.47%
After Hours: 8.60 +0.14 +1.65% 17:52 03/08 EST
OPEN
8.92
PREV CLOSE
8.95
HIGH
9.07
LOW
8.44
VOLUME
1.98M
TURNOVER
--
52 WEEK HIGH
10.88
52 WEEK LOW
1.950
MARKET CAP
1.69B
P/E (TTM)
-30.7860
1D
5D
1M
3M
1Y
5Y
Follicular Lymphoma Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Mar 08, 2021 (Market Insight Reports) -- The report for Follicular Lymphoma Treatment offers an assiduous analysis of contemporary market trends, driving...
Market Insight Reports · 10h ago
10-K: IMMUNOGEN, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Overview We are a clinical-stage...
Edgar Online - (EDG = 10Q, 10K) · 03/01 21:44
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 03/01 21:30
ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference
BusinessWire - BZX · 02/24 21:30
Antibody-drug Conjugates Market is set for Lucrative Growth | Top Companies -ImmunoGen, Takeda.
Feb 17, 2021 (The Expresswire) -- Antibody-drug Conjugates Market size was $1,387 million in 2016 and is expected to reach $3,198 million in 2027 with CAGR...
The Express Wire · 02/17 12:59
Immunogen Inc Has Returned 12.5% Since SmarTrend Recommendation (IMGN)
SmarTrend identified an Uptrend for Immunogen Inc (NASDAQ:IMGN) on January 19th, 2021 at $7.67. In approximately 4 weeks, Immunogen Inc has returned 12.46% as of today's recent price of $8.62.
Comtex SmarTrend(R) · 02/17 05:33
Mantle Cell Lymphoma Treatment Market 2021 Growth Analysis, Share, Demand by Regions, Types and Analysis of Key Players- Research Forecasts To 2027
The Express Wire · 02/15 12:46
News Flash: Analysts Just Made An Incredible Upgrade To Their ImmunoGen, Inc. (NASDAQ:IMGN) Forecasts
Simply Wall St. · 02/15 04:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMGN. Analyze the recent business situations of ImmunoGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMGN stock price target is 10.21 with a high estimate of 17.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 341
Institutional Holdings: 183.50M
% Owned: 91.87%
Shares Outstanding: 199.73M
TypeInstitutionsShares
Increased
57
34.06M
New
55
7.73M
Decreased
72
10.44M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.04%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Director
Stephen McCluski
President/Chief Executive Officer/Director
Mark Enyedy
Chief Financial Officer/Senior Vice President
Susan Altschuller
Senior Vice President
Anna Berkenblit
Senior Vice President
Stacy Coen
Senior Vice President
Theresa Wingrove
Vice President
Thomas Ryll
Independent Director
Stuart Arbuckle
Independent Director
Mark Goldberg
Independent Director
Dean Mitchell
Independent Director
Kristine Peterson
Independent Director
Richard Wallace
No Data
About IMGN
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.

Webull offers kinds of ImmunoGen, Inc. stock information, including NASDAQ:IMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMGN stock methods without spending real money on the virtual paper trading platform.